BioSpace News Archive

A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.

Independent SMO Panthera Biopartners has opened its first clinical trials site in Preston, Lancashire, UK.

Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs

MorphoSys AG announced presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida.

Carestream will introduce a three-dimensional extension of general radiography through its Digital Tomosynthesis functionality clearance) at this year’s Radiological Society of North America conference in booth #7513, North Hall..

The good performance we saw in the second quarter has continued and further improved.

HHS stated that Gilead had “willfully and deliberately induced infringement of the HHS patents.” As a result, “Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP,” through the sale of Truvada and Descovy.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

PromoCell, a premier manufacturer of human primary cells and cell culture products, now offers cell disease models covering a wide range of diseases including diabetes type 1 and 2, respiratory diseases such as COPD and asthma, as well as cardiomyopathy disease.

Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.